Soligenix logo
Soligenix SNGX
$ 1.08 -10.74%

Quarterly report 2025-Q3
added 11-07-2025

report update icon

Soligenix Financial Ratios 2011-2026 | SNGX

Annual Financial Ratios Soligenix

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.8 -0.4 -0.1 -2.4 -5.1 -1.3 -1.9 -2.7 -2.9 -3.5 -3.5 -4.4 -3.7

P/S

5.7 5.8 2.1 18.1 10.3 2.3 2.5 0.8 2.6 3.4 11.0 5.8 1.1

EPS

-0.8 -4.8 -4.7 -0.6 -0.5 -0.7 -1.2 -0.9 -3 -0.3 -0.7 -0.4 -0.2

EV (Enterprise Value)

3.64 M 8.93 M -8.13 M 40.1 M 48.6 M 7.09 M 9.06 M 2.94 M 25.4 M 25.3 M 39.7 M 16.2 M 4.2 M

EBITDA per Share

-0.99 -4.96 -4.9 -0.674 -0.541 -0.684 -1.22 -1.61 -2.63 -3.16 -4.48 -4 -2.5

EV/EBITDA

0.8 -1.8 -4.0 -0.3 -0.8 -0.0 -2.7 -2.8 -4.3 -3.4 -1.0

PEG

-0.01 -0.0 -0.0 0.07 -0.17 -0.03 0.08 -0.04 -0.47 -0.07 0.05 0.06 -0.05

P/B

1.9 -2.2 0.2 11.4 32.7 1.9 2.2 1.2 -1252.8 -154.2 -20.1 5.2 1.3

P/CF

-0.6 -0.4 -0.2 -3.7 -6.3 -1.6 -2.1 -1.8 -4.2 -9.4 -7.9 -7.0 -4.2

ROE %

-243.45 558.45 -117.05 -472.72 -642.05 -141.72 -113.09 -43.87 42772.57 4358.32 568.36 -117.23 -35.03

ROA %

-62.68 -96.63 -46.71 -88.93 -120.32 -84.83 -74.84 -31.61 -106.01 -96.44 -121.70 -88.48 -28.92

ROCE %

-305.18 576.28 -122.16 -134.58 -720.37 -144.25 -120.16 -77.19 38834.87 4393.65 404.37 -132.09 -43.59

Current Ratio

1.3 0.9 1.7 3.2 1.2 2.5 2.9 3.5 1.0 0.9 0.8 3.3 5.0

DSO

- - - 87.4 115.3 83.7 90.2 42.2 82.6 41.2 183.1 39.4 44.6

DPO

1224.1 2250.1 1266.2 426.9 279.9 168.8 148.5 73.9 232.3 206.3 218.1 158.3 225.7

Operating Cycle

- - - 87.4 115.3 83.7 90.2 42.2 82.6 41.2 183.1 39.4 44.6

Cash Conversion Cycle

-1224.0 -2250.1 -1266.2 -339.5 -164.6 -85.1 -58.3 -31.8 -149.7 -165.1 -35.0 -118.9 -181.1

All numbers in USD currency

Quarterly Financial Ratios Soligenix

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.58 -0.82 -1.06 - -0.78 -1.31 -2.91 - -2.56 -3.56 -0.36 - -1.15 -0.83 -1.52 - -0.09 -0.05 -0.06 - -0.06 -0.1 -0.32 - -0.14 -0.12 -0.09 - -0.11 -0.18 -0.27 - -0.17 -0.41 -0.32 - -0.49 -0.03 -0.37 - 1.05 -0.15 -0.19 - -0.21 -0.05 -0.17 - -0.34 -0.28 -0.1 - -0.07 -0.09 -0.13 - 0.2 -0.18 -0.16

EBITDA per Share

- - - - - - - - - - - - -1.07 -1.18 -1.46 - -0.08 -0.07 -0.06 - -0.06 -0.1 -0.36 - -0.14 -0.12 -0.13 - -0.11 -0.18 -0.27 - -0.17 -0.41 -0.31 - -0.43 -0.31 -0.6 - -0.46 -0.08 -0.06 - -0.25 -0.08 -0.08 - -0.09 -0.22 -0.09 - -0.06 -0.08 -0.12 - 0.21 -0.17 -0.15

ROE %

-299.61 -295.27 -195.00 -325.70 -365.09 -375.51 -355.84 -36.30 -356.94 -638.19 -667.14 -443.44 -467.27 -170.46 -125.87 -49.64 -97.48 -121.49 -183.53 -324.66 -511.38 -650.26 -721.79 -444.98 -474.62 -317.54 -196.59 -92.28 -107.52 -93.11 -104.91 -79.25 -101.87 -109.25 -73.92 -39.41 -15192.33 -30322.63 -8596.03 31529.13 34355.55 52334.89 31225.91 5607.80 5978.45 3522.67 3098.71 624.49 603.12 211.10 -8.90 -89.48 -60.09 -9.32 -10.17 -24.38 29.39 -28.44 -25.33

ROA %

-127.51 -121.51 -91.28 -56.85 -71.56 -69.86 -64.85 -35.79 -54.23 -57.96 -57.50 -48.01 -60.08 -53.71 -48.92 -25.97 -34.97 -31.89 -39.45 -61.07 -96.07 -122.06 -135.41 -83.39 -101.13 -83.89 -71.41 -55.24 -65.32 -57.66 -67.03 -52.44 -68.74 -74.95 -51.65 -28.40 9.16 63.01 10.07 -78.15 -140.69 -240.79 -200.59 -124.09 -203.46 -220.28 -247.84 -133.72 -149.85 -86.61 -66.24 -67.54 -40.72 2.22 -0.44 -17.59 26.81 -23.48 -20.92

ROCE %

-308.19 -305.66 -204.89 -357.31 -399.46 -410.18 -387.93 -6.76 -305.33 -561.75 -614.37 -442.97 -465.32 -189.10 -127.54 -54.41 -102.86 -128.95 -184.99 -350.11 -539.97 -681.39 -754.76 -496.29 -526.84 -367.52 -244.25 -93.98 -109.32 -94.11 -105.47 -79.51 -99.77 -104.69 -81.68 -59.68 6874.98 13829.89 24956.94 26558.98 29899.95 26306.26 16294.85 5476.10 5581.23 2345.40 1399.13 322.32 300.91 174.37 -8.99 -89.63 -60.26 -9.47 -10.29 -24.46 29.37 -28.46 -25.37

Current Ratio

3.1 1.5 1.9 1.9 2.3 1.5 - 1.4 1.6 1.7 0.8 0.8 1.1 1.2 1.4 1.7 2.0 2.1 2.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 2.5 2.5 2.5 2.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.0 0.5 -

DPO

- - - - - - - - 1624.8 1299.5 1339.2 - 2927.6 2043.8 3683.0 - 929.7 630.3 1294.0 - 502.7 534.9 267.6 - 258.5 229.7 239.0 - 156.8 129.9 180.8 - 108.5 236.3 145.3 - 59.3 66.5 93.6 - 108.4 489.4 638.7 - 129.9 264.9 328.1 - 564.2 262.8 162.3 - 134.7 166.5 199.0 - 181.6 340.3 -

Operating Cycle

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.0 0.5 -

Cash Conversion Cycle

- - - - - - - - -1624.8 -1299.5 -1339.2 - -2927.6 -2043.8 -3683.0 - -929.7 -630.3 -1294.0 - -502.7 -534.9 -267.6 - -258.5 -229.7 -239.0 - -156.8 -129.9 -180.8 - -108.5 -236.3 -145.3 - -59.3 -66.5 -93.6 - -108.4 -489.4 -638.7 - -129.9 -264.9 -328.1 - -564.2 -262.8 -162.3 - -134.7 -166.5 -199.0 - -181.5 -339.8 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Soligenix, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.06 - $ 28.2 B japanJapan
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.44 -0.46 % $ 909 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 5.03 -3.08 % $ 215 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 67.0 -0.3 % $ 2.8 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Theravance Biopharma Theravance Biopharma
TBPH
$ 14.9 -1.91 % $ 750 M cayman-islandsCayman-islands
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.2 -6.97 % $ 306 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 51.31 -2.65 % $ 8.08 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 14.64 -2.2 % $ 574 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.07 -2.29 % $ 21.9 M israelIsrael
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 28.76 -3.43 % $ 32.9 B israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Equillium Equillium
EQ
$ 2.03 -1.46 % $ 116 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 23.81 1.51 % $ 641 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 46.38 -2.45 % $ 4.17 B schweizSchweiz